XHKG
2251
Market cap109mUSD
Oct 09, Last price
9.00HKD
1D
5.88%
1Q
-14.61%
IPO
-85.44%
Name
Beijing Airdoc Technology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
Key people
Chao He
Chief Technology Officer, Executive Director · since 2024
Yong Qin
Executive Director
Lin Wang
Executive Director · since 2023
Yubo Wei
Executive Director · since 2025
Dalei Zhang
Executive Chairman of the Board, Chief Executive Officer · since 2021
Mingqiang Chen
Chief Research and Development Officer · since 2020
Joint Company Secretary · since 2022
Xinfeng Wang
Joint Company Secretary · since 2025
Yanlin Huang
Non-Executive Independent Director · since 2021
Ho Yin Ng
Non-Executive Independent Director · since 2024
Yangfeng Wu
Non-Executive Independent Director · since 2021
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||